The early backer of companies such as Achillion Pharmaceuticals Inc. and Intercept Pharmaceuticals Inc. closed a new $500 million fund, the latest sign that biotech venture-capital investing is on course for a record year.
Clarus Ventures’ new fund, announced Tuesday, will focus on opthalmology, oncology and rare diseases. It follows funding raises this year of $537 million for Flagship Ventures, $400 million for MPM Capital and $280 million for Atlas Venture.
